Antipseudomonal Agents: IV and Oral Formulations
Ciprofloxacin is the only fluoroquinolone with reliable oral and IV antipseudomonal activity, while levofloxacin has weaker activity against Pseudomonas aeruginosa and should be considered a second-line oral option. 1, 2
Oral Antipseudomonal Agents
Fluoroquinolones (Primary Oral Option)
- Ciprofloxacin 750 mg orally every 12 hours is the preferred oral antipseudomonal agent, offering superior activity compared to other fluoroquinolones 1, 2
- Ciprofloxacin achieves comparable serum levels with oral and IV administration due to high bioavailability, and penetrates well into lung tissue with sputum concentrations reaching 46-90% of serum levels 3, 4
- Levofloxacin has activity against P. aeruginosa but is generally less potent than ciprofloxacin, with 75% of isolates susceptible compared to 82% for ciprofloxacin 4, 5, 6
- Ofloxacin is the least active fluoroquinolone against Pseudomonas and should not be relied upon 6
Important Limitations of Oral Therapy
- Oral ciprofloxacin monotherapy should be limited to mild-to-moderate infections in immunocompetent patients with confirmed susceptibility 2
- Rapid emergence of resistance is a significant concern with fluoroquinolone monotherapy, particularly more problematic than with IV combination therapy 1
- For seriously affected patients, conventional IV therapy is significantly better than oral quinolone treatment 1
Intravenous Antipseudomonal Agents
Beta-Lactams (First-Line IV Options)
- Piperacillin-tazobactam 3.375-4.5g IV every 6 hours is the preferred first-line agent for most Pseudomonas infections 7, 4
- Ceftazidime 2g IV every 8 hours (or 150-250 mg/kg/day divided in 3-4 doses, maximum 12g daily) 7, 4
- Cefepime 2g IV every 8-12 hours (or 100-150 mg/kg/day divided in 2-3 doses, maximum 6g daily) 7, 4
- Meropenem 1g IV every 8 hours (or 60-120 mg/kg/day divided in 3 doses, maximum 6g daily, can escalate to 3 × 2g in severe cases) 7, 4
- Imipenem/cilastatin 1g IV every 8 hours (or 50-100 mg/kg/day divided in 3-4 doses, maximum 4g daily), though less preferred due to higher allergic reaction rates 7, 4
- Aztreonam 2g IV every 8 hours is the only monobactam with antipseudomonal activity and can be used in severe penicillin allergy 4
Fluoroquinolones (IV Formulations)
- Ciprofloxacin 400mg IV every 8-12 hours is available for patients unable to take oral therapy 3, 2, 4
- Levofloxacin 750mg IV daily is less potent but available IV 4, 8
Aminoglycosides (Combination Therapy)
- Tobramycin 5-7 mg/kg IV daily (or ~10 mg/kg/day) is the preferred aminoglycoside, with once-daily dosing equally efficacious and less toxic than three-times-daily dosing 7, 4
- Amikacin 15-20 mg/kg IV daily is an alternative aminoglycoside option 7, 4
- Gentamicin is less desirable than tobramycin due to higher nephrotoxicity 1, 4
- All aminoglycosides require therapeutic drug monitoring with target tobramycin peak levels of 25-35 mg/mL 7, 4
Polymyxins (Multidrug-Resistant Strains)
- Colistin 1-2 million units IV (5mg CBA/kg loading dose, then 2.5mg CBA maintenance) for multidrug-resistant strains 7, 4
Agents Available in BOTH IV and Oral Formulations
Only fluoroquinolones are available in both IV and oral formulations with antipseudomonal activity:
- Ciprofloxacin: 400mg IV every 8-12 hours OR 750mg orally every 12 hours 3, 2, 4
- Levofloxacin: 750mg IV or orally daily (though less potent against Pseudomonas) 3, 4, 8
Critical Agents That LACK Antipseudomonal Activity
Avoid these common pitfalls—the following agents do NOT cover Pseudomonas despite being broad-spectrum:
- Ceftriaxone and cefazolin have no antipseudomonal activity 7, 4
- Ertapenem explicitly lacks antipseudomonal coverage despite being a carbapenem 7, 4
- Ampicillin/sulbactam has no clinically relevant activity against P. aeruginosa 7
- Most streptococcal-focused, enterococcal, and anaerobic coverage drugs are ineffective 7
When to Use Combination Therapy vs. Monotherapy
Monotherapy Appropriate For:
- Mild-to-moderate infections in immunocompetent patients with confirmed susceptibility 2
- Non-severe infections after susceptibility results confirm single-agent activity 4
Combination Therapy Required For:
- Critically ill patients or septic shock 7, 4
- Ventilator-associated or nosocomial pneumonia 7, 4
- Structural lung disease (bronchiectasis, cystic fibrosis) 7, 4
- Prior IV antibiotic use within 90 days 7, 4
- Documented Pseudomonas on Gram stain 7
- High local prevalence of multidrug-resistant strains 7
Recommended Combinations:
- Antipseudomonal β-lactam PLUS ciprofloxacin 9, 7, 4
- Antipseudomonal β-lactam PLUS aminoglycoside (tobramycin preferred) 7, 4
- Combination therapy delays resistance development compared to monotherapy 7, 4
Treatment Duration and Transition Strategy
- Standard duration: 7-14 days for most Pseudomonas infections, with 10-14 days preferred for pneumonia or bloodstream infections 2, 7, 4
- Switch from IV to oral ciprofloxacin by day 3 if clinically stable, as oral bioavailability matches IV levels 2
- De-escalate to monotherapy once susceptibility results are available if the patient is improving and the organism is susceptible 9, 7, 4
Special Dosing Considerations
- Cystic fibrosis patients require higher doses due to altered pharmacokinetics: ceftazidime 150-250 mg/kg/day, meropenem 60-120 mg/kg/day 7, 4
- Maximum recommended doses should be used for severe infections to avoid underdosing and treatment failure 7, 4
- Aminoglycoside monotherapy should NEVER be used for empirical coverage or bacteremia due to rapid resistance emergence 4